MetaCap

C4 Therapeutics (CCCC) vs X4 Pharmaceuticals (XFOR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

C4 Therapeutics (CCCC) has outperformed X4 Pharmaceuticals (XFOR) over the past year, gaining 1.6% versus a loss of 20.0%. Over five years, CCCC leads with a -93.2% price change compared with -97.8% for XFOR. C4 Therapeutics is the larger company by market cap ($325.7 million vs $306.3 million), about 1.1 times the size, while X4 Pharmaceuticals is growing revenue faster (+150.0% vs +1.0%).

C4 Therapeutics converts more of its revenue into profit, with a net margin of -292.1% versus -1218.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CCCC+1.64%XFOR-20.00%
+98%+28%-41%
Nov 21, 20251 yearNov 20, 2026
CCCC-93.55%XFOR-97.91%
+5%-50%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CCCC versus XFOR key metrics
MetricCCCCXFOR
Share price$2.48$3.00
Market cap$325.67M$306.34M
1-day change+1.64%+1.35%
YTD return+29.84%-25.00%
1-year return+1.64%-20.00%
5-year return-93.23%-97.79%
P/E ratio (TTM)—5.45
EPS (TTM)$-0.63$0.55
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$35.95M$6.50M
Revenue growth (YoY)+1.02%+150.00%
Net income (latest FY)$-104.99M$-79.20M
Gross margin—11.43%
Operating margin-320.53%-1336.66%
Net margin-292.08%-1218.45%
52-week high$5.17$4.83
52-week low$1.69$2.43
Distance from 52-week high-52.03%-37.89%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+404.03%+286.67%
Average volume2.57M877.70K
Shares outstanding131.32M102.11M
Employees10445
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CCCC has outperformed XFOR by 21.6 percentage points over the past year.
  • C4 Therapeutics is more profitable, keeping -292.1 cents of every revenue dollar as net income versus -1218.4 cents for X4 Pharmaceuticals.
  • X4 Pharmaceuticals grew revenue faster in its latest fiscal year (+150.00% vs +1.02%).

About C4 Therapeutics

CCCC stock →

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 104 employees

About X4 Pharmaceuticals

XFOR stock →

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 45 employees

CCCC vs XFOR FAQ

Which is bigger, C4 Therapeutics or X4 Pharmaceuticals?

C4 Therapeutics (CCCC) is larger, with a market capitalization of $325.67M compared with $306.34M for X4 Pharmaceuticals (XFOR).

Which stock has performed better over the past year, CCCC or XFOR?

CCCC returned +1.64% over the past 12 months, compared with -20.00% for XFOR (price return, excluding dividends). Past performance does not predict future results.

Are C4 Therapeutics and X4 Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons